Tag Archives: Louise Chen

Melinta Therapeutics Inc (MLNT) Receives a Buy from Cantor Fitzgerald

Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Melinta Therapeutics Inc (MLNT – Research Report) today and set a price target of $15. The company’s shares opened today at $4.63, close to its 52-week low of $3.22. Chen

Cantor Fitzgerald Sticks to Its Buy Rating for Spero Therapeutics Inc (SPRO)

In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Spero Therapeutics Inc (SPRO – Research Report), with a price target of $27. The company’s shares opened today at $11.38. Chen commented: “. Post a

Perrigo Company plc (PRGO) Gets a Buy Rating from Cantor Fitzgerald

In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Perrigo Company plc (PRGO – Research Report), with a price target of $107. The company’s shares opened today at $49.18. Chen wrote: “We rate PRGO

Cantor Fitzgerald Thinks Foamix Pharma’s Stock is Going to Recover

In a report released yesterday, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Foamix Pharma (FOMX – Research Report), with a price target of $15. The company’s shares closed yesterday at $3.15, close to its 52-week low of

Dermira (DERM) Receives a Buy from Cantor Fitzgerald

In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Dermira (DERM – Research Report), with a price target of $25. The company’s shares closed yesterday at $10.42. Chen said: “DERM is a leading dermatology

Cantor Fitzgerald Sticks to Its Buy Rating for Menlo Therapeutics Inc (MNLO)

In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Menlo Therapeutics Inc (MNLO – Research Report), with a price target of $25. The company’s shares opened today at $7. Chen commented: “. After a